Physician profile
Daksha Vyas
NPI 1922190859
$8,043.00
in general payments reported to CMS, 2019-2025
52 companies · $2,020 in 2025
The $2,020 reported for 2025 was more than what 79% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,373 · 2020: $732 · 2021: $1,602 · 2022: $869 · 2023: $495 · 2024: $953 · 2025: $2,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,450 · Education: $18.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,449.73 |
| Education | $18.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $974.39 | 2021-2025 | Botox, Ubrelvy |
| Biogen, INC. | $884.70 | 2019-2025 | Vumerity, Tysabri |
| Novartis Pharmaceuticals Corporation | $479.59 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $443.47 | 2024-2025 | Hyqvia |
| Sunovion Pharmaceuticals INC. | $428.73 | 2019-2022 | |
| Ucb, INC. | $403.12 | 2019-2023 | Briviact |
| Sk Life Science, INC. | $401.14 | 2020-2025 | Xcopri |
| Genentech USA, INC. | $294.55 | 2021-2025 | Ocrevus Zunovo, Ocrevus |
| Argenx US, INC. | $289.82 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Janssen Pharmaceuticals, INC | $255.21 | 2020-2025 | |
| Eisai INC. | $240.61 | 2019-2025 | |
| Lilly USA, LLC | $236.71 | 2019-2025 | Kisunla, Amyvid, Reyvow |
| Abbott Laboratories | $218.38 | 2019-2022 | |
| Genzyme Corporation | $217.66 | 2019-2021 | |
| Emd Serono, INC. | $216.36 | 2019-2025 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $156.50 | 2020-2024 | Rexulti, Vyepti |
| Avanir Pharmaceuticals, INC. | $122.51 | 2019 | |
| Alexion Pharmaceuticals, INC. | $117.57 | 2019-2025 | Ultomiris |
| Pfizer INC. | $107.54 | 2019-2024 | |
| Neurelis, INC. | $105.12 | 2023-2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $95.47 | 2019-2025 | Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $90.45 | 2021 | |
| Amgen INC. | $88.19 | 2020-2024 | Uplizna |
| Alnylam Pharmaceuticals INC. | $74.22 | 2020-2021 | |
| Livanova USA, INC. | $71.09 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Ani Pharmaceuticals, INC. | $65.24 | 2025 | Purified Cortrophin Gel |
| Janssen Biotech, INC. | $58.52 | 2025 | |
| Almatica Pharma LLC | $57.60 | 2021 | |
| Aucta Pharmaceuticals, INC. | $57.53 | 2025 | Motpoly Xr |
| Ceribell, INC. | $53.94 | 2024 | Pocket Eeg Device |
| Acadia Pharmaceuticals INC | $51.70 | 2019-2023 | Nuplazid |
| Cycle Pharmaceuticals INC | $51.03 | 2025 | Tascenso Odt |
| Astrazeneca Pharmaceuticals LP | $50.87 | 2021 | |
| Acorda Therapeutics, INC | $49.27 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $48.05 | 2019-2021 | |
| Corium, LLC | $47.78 | 2022-2023 | Adlarity |
| Impel Pharmaceuticals LLC | $47.18 | 2024-2025 | Trudhesa |
| Otsuka America Pharmaceutical, INC. | $46.17 | 2023 | Rexulti, Nuedexta |
| Akcea Therapeutics, INC. | $39.69 | 2020 | |
| Jazz Pharmaceuticals INC. | $38.60 | 2025 | |
| Chiesi USA, INC. | $37.15 | 2025 | Kengreal, Cleviprex |
| Zogenix INC. | $29.64 | 2021 | |
| Allergan, INC. | $26.66 | 2020 | |
| Tg Therapeutics, INC. | $24.41 | 2023 | |
| Celgene Corporation | $23.54 | 2025 | Zeposia |
| Glaxosmithkline, LLC. | $20.05 | 2025 | Trelegy Ellipta |
| Banner Life Sciences, LLC | $19.95 | 2023 | |
| Axsome Therapeutics, INC. | $19.74 | 2025 | Symbravo |
| Bayer Healthcare Pharmaceuticals INC. | $18.75 | 2019 | |
| Neurocrine Biosciences, INC. | $17.79 | 2020 | |
| Amneal Pharmaceuticals LLC | $15.68 | 2024 | Rytary |
| Mdd US Operations, LLC | $13.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daksha Vyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.